130 related articles for article (PubMed ID: 23988776)
1. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.
Warth A; Penzel R; Lindenmaier H; Brandt R; Stenzinger A; Herpel E; Goeppert B; Thomas M; Herth FJ; Dienemann H; Schnabel PA; Schirmacher P; Hoffmann H; Muley T; Weichert W
Eur Respir J; 2014 Mar; 43(3):872-83. PubMed ID: 23988776
[TBL] [Abstract][Full Text] [Related]
2. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2014 May; 50(7):1361-9. PubMed ID: 24548766
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
[TBL] [Abstract][Full Text] [Related]
4. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
[TBL] [Abstract][Full Text] [Related]
6. Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas.
Rossi G; Cavazza A; Righi L; Sartori G; Bisagni A; Longo L; Pelosi G; Papotti M
Int J Surg Pathol; 2014 Aug; 22(5):401-7. PubMed ID: 24651909
[TBL] [Abstract][Full Text] [Related]
7. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract][Full Text] [Related]
9. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas.
Okayama H; Kohno T; Ishii Y; Shimada Y; Shiraishi K; Iwakawa R; Furuta K; Tsuta K; Shibata T; Yamamoto S; Watanabe S; Sakamoto H; Kumamoto K; Takenoshita S; Gotoh N; Mizuno H; Sarai A; Kawano S; Yamaguchi R; Miyano S; Yokota J
Cancer Res; 2012 Jan; 72(1):100-11. PubMed ID: 22080568
[TBL] [Abstract][Full Text] [Related]
10. HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
Reis H; Herold T; Ting S; Worm K; Huber U; Christoph DC; Eberhardt WE; Kostbade K; Kasper S; Stamatis G; Welter S; Darwiche K; Karpf-Wissel R; Theegarten D; Schmid KW; Schuler M; Wiesweg M
Lung Cancer; 2015 Apr; 88(1):34-41. PubMed ID: 25708529
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma.
Hwang DH; Szeto DP; Perry AS; Bruce JL; Sholl LM
Arch Pathol Lab Med; 2014 May; 138(5):626-35. PubMed ID: 23738762
[TBL] [Abstract][Full Text] [Related]
12. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
[TBL] [Abstract][Full Text] [Related]
13. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
[TBL] [Abstract][Full Text] [Related]
14. Toward personalized medicine of lung cancer: response to nontargeted therapy in invasive pulmonary adenocarcinoma as a function of tumor cell differentiation.
Hartel PH; Hartel JV; Fanburg-Smith JC; Gilmore RW; Fleming D; Barnett S; Mudry R; Parker JE
Int J Surg Pathol; 2013 Jun; 21(3):224-8. PubMed ID: 23637254
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma.
Shan L; Qiu T; Ling Y; Guo L; Zheng B; Wang B; Li W; Li L; Ying J
PLoS One; 2015; 10(6):e0130447. PubMed ID: 26102513
[TBL] [Abstract][Full Text] [Related]
16. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
Tam IY; Chung LP; Suen WS; Wang E; Wong MC; Ho KK; Lam WK; Chiu SW; Girard L; Minna JD; Gazdar AF; Wong MP
Clin Cancer Res; 2006 Mar; 12(5):1647-53. PubMed ID: 16533793
[TBL] [Abstract][Full Text] [Related]
17. Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung.
Lee JG; Kim S; Shim HS
Lung Cancer; 2012 Jul; 77(1):156-61. PubMed ID: 22418245
[TBL] [Abstract][Full Text] [Related]
18. No impact of passive smoke on the somatic profile of lung cancers in never-smokers.
Couraud S; Debieuvre D; Moreau L; Dumont P; Margery J; Quoix E; Duvert B; Cellerin L; Baize N; Taviot B; Coudurier M; Cadranel J; Missy P; Morin F; Mornex JF; Zalcman G; Souquet PJ;
Eur Respir J; 2015 May; 45(5):1415-25. PubMed ID: 25745045
[TBL] [Abstract][Full Text] [Related]
19. Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid.
Frankel D; Nanni-Metellus I; Robaglia-Schlupp A; Tomasini P; Guinde J; Barlesi F; Astoul P; Ouafik L; Amatore F; Secq V; Kaspi E; Roll P
Clin Chem Lab Med; 2018 Apr; 56(5):851-856. PubMed ID: 29306909
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.
Rodriguez EF; VandenBussche CJ; Chowsilpa S; Maleki Z
Cancer Cytopathol; 2018 Oct; 126(10):853-859. PubMed ID: 30199148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
